Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease
| Autor: | Andrew Khalil, Jennifer Peugh, Karen E Hansen, Micah R Chan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Parathyroidectomy
medicine.medical_specialty TERIPARATIDE Endocrinology Diabetes and Metabolism medicine.medical_treatment Urology Parathyroid hormone chemistry.chemical_element Case Report Case Reports Diseases of the musculoskeletal system Calcium Bone remodeling ADYNAMIC BONE DISEASE CKD‐MBD HYPERCALCEMIA DIALYSIS medicine Teriparatide Orthopedics and Sports Medicine Renal osteodystrophy Bone mineral Orthopedic surgery business.industry fungi medicine.disease chemistry RC925-935 business Primary hyperparathyroidism RD701-811 medicine.drug |
| Zdroj: | JBMR Plus, Vol 3, Iss 7, Pp n/a-n/a (2019) JBMR Plus |
| ISSN: | 2473-4039 |
| Popis: | Hypercalcemia most often results from primary hyperparathyroidism and malignancy. Adynamic bone disease (ABD) is a form of renal osteodystrophy characterized by reduced bone turnover, which can limit the ability of bone to release or store calcium, potentially leading to low, normal, or high serum calcium levels. We describe a 51‐year‐old dialysis‐dependent female with hypercalcemia after parathyroidectomy. A demeclocycline‐labeled bone biopsy confirmed adynamic bone disease. Teriparatide, a recombinant form of parathyroid hormone (PTH) used to treat postmenopausal osteoporosis, was prescribed for 12 months and normalized serum calcium levels. Although previous case reports and series have described favorable changes in spine bone mineral density when teriparatide was prescribed for ABD, ours is the first documented case in which teriparatide resolved hypercalcemia due to ABD. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text